Avantor® Discusses Cell & Gene Therapy Production Trends Through the Lens of COVID-19
Avantor executives participated in the Cell & Gene Therapy Bioprocessing & Commercialization Conference, discussing essential topics like process efficiency and scalability within the biopharmaceutical sector.
Dr. Ger Brophy highlighted the need for operational efficiency and automation to enhance accessibility to cell and gene therapies. Claudia Berrón emphasized collaboration among industry leaders to navigate challenges posed by COVID-19, focusing on supply chain disruptions and clinical trial delays. Avantor aims to support the development of novel treatments by partnering with leading pharmaceutical companies.
- Executives engaged in a high-profile conference, enhancing industry visibility.
- Focus on operational efficiencies aligns Avantor with industry trends in biopharma.
- Commitment to collaboration could improve treatment production timelines.
- COVID-19 challenges highlighted could suggest ongoing operational vulnerabilities.
- Disruption of clinical trials may affect future revenue streams.
Avantor executives joined other industry leaders at virtual Cell & Gene Therapy Bioprocessing & Commercialization Conference
Panels discussed critical topics including process efficiency and scaling solutions
RADNOR, Pa., Nov. 2, 2020 /PRNewswire/ -- Executives from Avantor Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences, advanced technologies and applied materials industries, recently provided expert insight at the Cell & Gene Therapy Bioprocessing & Commercialization Virtual Conference. Cell and gene therapy (C>) are two of the most revolutionary applications driving the biopharmaceutical industry.
In separate panel discussions with other global industry leaders, Dr. Ger Brophy, EVP, Biopharma Production at Avantor and Claudia Berrón, SVP, Business Development and Commercial Operations at Avantor, each addressed novel considerations and challenges facing the biopharmaceutical industry, including the impact of COVID-19. They highlighted innovation to help drive the creation and commercialization of life-changing, personalized C> treatments.
In a panel on the evolution of C> and the path toward scalability and manufacturability of these treatments, Dr. Brophy gave his perspective on this growing need for the bioprocessing industry.
"Genuine progress is being made in the long-standing battle to effectively treat and control disease, and cell & gene therapies will only continue to unlock new frontiers in medicine," said Dr. Brophy. "We're beginning to see more clearly the issues that need to be addressed, and know that if products are to scale and become more accessible to patients worldwide, there needs to be efficiency in operations. There is an absolute requirement for automation, both to reduce variability and to generate process efficiencies. At Avantor, we are ready to make the essential materials and technologies available to companies leading the charge and treating patients. Innovation and agility are central to how we're partnering with the industry to resolve these issues."
On a separate panel, Ms. Berrón highlighted how the industry is navigating the challenges and impact of the global pandemic, from the fragmentation of supply chains to clinical trial disruption.
"In this critical moment for the industry and the world, it is more important than ever for leaders in the cell & gene therapy community to come together to strategize and share ideas," said Ms. Berrón. "Avantor is actively working with the world's leading pharmaceutical and biotechnology companies to accelerate the production of novel treatments. Collectively, our goal is to mitigate any challenges in the process of taking a groundbreaking treatment from its initial scientific discovery to delivery in treating patients."
Avantor provides products for biopharma production workflows, including cell and gene therapy offering. Search 'Avantor biopharma' in your browser.
About Avantor
Avantor®, a Fortune 500 company, is a leading global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. Our portfolio is used in virtually every stage of the most important research, development and production activities in the industries we serve. One of our greatest strengths comes from having a global infrastructure that is strategically located to support the needs of our customers. Our global footprint enables us to serve more than 225,000 customer locations and gives us extensive access to research laboratories and scientists in more than 180 countries. We set science in motion to create a better world. For information, visit avantorsciences.com and find us on LinkedIn, Twitter and Facebook.
Robert Donohoe
Senior Director, Corporate Communications
Avantor
M: 484-688-4730
Robert.Donohoe@avantorsciences.com
Source: Avantor and Financial News
View original content:http://www.prnewswire.com/news-releases/avantor-discusses-cell--gene-therapy-production-trends-through-the-lens-of-covid-19-301164547.html
SOURCE Avantor and Financial News
FAQ
What did Avantor discuss at the Cell & Gene Therapy Conference?
Who from Avantor spoke at the Cell & Gene Therapy Conference?
How does COVID-19 impact Avantor's business operations?
What is Avantor's strategy for innovation in biopharma?
What is the stock symbol for Avantor?
